Biotech Daily - Archive
More Posts
6 Posts
‘MARKED IMPROVEMENT’ FOR TISSUE THERAPIES’ 1st PATIENT
VENTRACOR’S PETER CROSBY HITS THE INVESTMENT ROAD
STEM CELL: ‘WORLD’S FIRST TRUE RAT EMBRYONIC STEM CELLS’
BIONOMICS ANXIOLYTIC BNC210 ‘EFFECTIVE IN 3 ANIMAL SPECIES’
BIO-SPRING: BDI-20 UP 14.3%, ALL ORDS UP 3.2%; BIG CAPS UP 29.4%
AGENIX REQUESTS ‘UP TO 2 MONTHS’ SUSPENSION
VENTRACOR’S PETER CROSBY HITS THE INVESTMENT ROAD
STEM CELL: ‘WORLD’S FIRST TRUE RAT EMBRYONIC STEM CELLS’
BIONOMICS ANXIOLYTIC BNC210 ‘EFFECTIVE IN 3 ANIMAL SPECIES’
BIO-SPRING: BDI-20 UP 14.3%, ALL ORDS UP 3.2%; BIG CAPS UP 29.4%
AGENIX REQUESTS ‘UP TO 2 MONTHS’ SUSPENSION
24 Posts
VENTRACOR REVENUE UP 163% TO $20m, LOSS DOWN 32%; NEEDS $20m
PHYLOGICA IMPROVES PHYLOMER POTENCY, HALF-LIFE
NEURODISCOVERY: NSL-101 'EFFECTIVE IN PAIN RELIEF’
PRIMA MEETS FDA FOR CANCER VACCINE APPLICATION
BIO-GUIDE: IF MARC SINATRA WAS KING OF CIRCADIAN
FDA WARNING PROMPTS MESOBLAST PIVOTAL SPINAL FUSION TRIAL
ANADIS SPRAY ‘SWITCHES-OFF’ MOUSE INFLUENZA VIRUS REPLICATION
PEPLIN APPOINTS TOM WIGGANS CEO; NEW CMO; RAISES $24m
DR IAN NISBET REFORMS XENOME FOR 2009 IPO
SCHERING-PLOUGH HALTS TWO ACRUX PROGRAMS
POLARTECHNICS DEMAND DOUBLES; RESULTS IMPROVE; US INTEREST
CSL TO PAY $3.1bn FOR TALECRIS PLASMA BUSINESS
PHARMAXIS BRONCHITOL IMPROVES CYSTIC FIBROSIS LUNG FUNCTION
TISSUE THERAPIES TREATS 1ST VITROGRO PATIENT
SOUTH AFRICA APPROVES VIRAX’S HIV VACCINE TRIAL
CEO INTERVIEW: BIONOMICS’ DR DEBORAH RATHJEN - ‘THIS IS JUST THE BEGINNING’
MESOBLAST CLAIMS LONG BONE STEM CELL SUCCESS
FDA BACKS QRX PLAN FOR TWO PHASE III DUAL-OPIOD TRIALS
ANTISENSE REQUESTS TYSABRI TRADING HALT
JULY BDI-20 BEATS ALL ORDS, AGAIN: HEARTWARE UP 54%, PROGEN DOWN 55%
BIOTA’S FLU DRUG EQUALS TAMIFLU, PREPARES FOR PHASE III
LANCET NEUROLOGY PUBLISHES PRANA’S ALZHEIMER’S EFFICACY
AVANTOGEN PLACEMENT TO INCREASE IN HAWAII BIOTECH
AGENIX CHINA’S HEADS TO ROLL, LEGAL ACTION BEGINS
PHYLOGICA IMPROVES PHYLOMER POTENCY, HALF-LIFE
NEURODISCOVERY: NSL-101 'EFFECTIVE IN PAIN RELIEF’
PRIMA MEETS FDA FOR CANCER VACCINE APPLICATION
BIO-GUIDE: IF MARC SINATRA WAS KING OF CIRCADIAN
FDA WARNING PROMPTS MESOBLAST PIVOTAL SPINAL FUSION TRIAL
ANADIS SPRAY ‘SWITCHES-OFF’ MOUSE INFLUENZA VIRUS REPLICATION
PEPLIN APPOINTS TOM WIGGANS CEO; NEW CMO; RAISES $24m
DR IAN NISBET REFORMS XENOME FOR 2009 IPO
SCHERING-PLOUGH HALTS TWO ACRUX PROGRAMS
POLARTECHNICS DEMAND DOUBLES; RESULTS IMPROVE; US INTEREST
CSL TO PAY $3.1bn FOR TALECRIS PLASMA BUSINESS
PHARMAXIS BRONCHITOL IMPROVES CYSTIC FIBROSIS LUNG FUNCTION
TISSUE THERAPIES TREATS 1ST VITROGRO PATIENT
SOUTH AFRICA APPROVES VIRAX’S HIV VACCINE TRIAL
CEO INTERVIEW: BIONOMICS’ DR DEBORAH RATHJEN - ‘THIS IS JUST THE BEGINNING’
MESOBLAST CLAIMS LONG BONE STEM CELL SUCCESS
FDA BACKS QRX PLAN FOR TWO PHASE III DUAL-OPIOD TRIALS
ANTISENSE REQUESTS TYSABRI TRADING HALT
JULY BDI-20 BEATS ALL ORDS, AGAIN: HEARTWARE UP 54%, PROGEN DOWN 55%
BIOTA’S FLU DRUG EQUALS TAMIFLU, PREPARES FOR PHASE III
LANCET NEUROLOGY PUBLISHES PRANA’S ALZHEIMER’S EFFICACY
AVANTOGEN PLACEMENT TO INCREASE IN HAWAII BIOTECH
AGENIX CHINA’S HEADS TO ROLL, LEGAL ACTION BEGINS
18 Posts
BIOGUIDE: CYTOPIA - FLYING UNDER THE RADAR
PROGEN HALTS PHASE III CANCER TRIAL; DUMPS PI-88, PI-166
LIVING CELL: ‘CLINICAL BENEFIT IN ALL TYPE 1 DIABETES PATIENTS’
BIOTA LOSES GSK LEGAL GAMBLE; BACK TO DRUG DEVELOPMENT
METABOLIC BECOMES POLYNOVO WITH $18m CASH
MEDIMMUNE EVALUATES NORWOOD VIROSOMAL VACCINE
NEUREN COMPLETES PHASE III GLYPROMATE DOSING
PROTEOME HALTS PROSTATE CANCER DIAGNOSTIC
GENETIC TECHNO ENFORCES CANCER TEST RIGHTS
GRAEME KAUFMAN: $400m FUND DELAYED, STILL BULLISH
TISSUE THERAPIES TO START PERTH TRIAL
GIACONDA HALTS PHASE IIa HEPATITIS C TRIAL
HUNTER IMMUNOLOGY READY FOR PHASE III COPD TRIAL
AVITA’S RECELL NEARS CHINESE REGISTRATION
PROGEN SPINS OUT PHARMASYNTH DRUG MANUFACTURING
SANOFI-AVENTIS PAYS $16m PLUS COSTS FOR UNILIFE’S SYRINGE
JUNE TOP 20 BEATS ALL ORDS; CHEMGENEX UP 30%, PORTLAND DOWN 57%
ANTISENSE, TEVA DATA: PHASE II MS DRUG SUCCESS
PROGEN HALTS PHASE III CANCER TRIAL; DUMPS PI-88, PI-166
LIVING CELL: ‘CLINICAL BENEFIT IN ALL TYPE 1 DIABETES PATIENTS’
BIOTA LOSES GSK LEGAL GAMBLE; BACK TO DRUG DEVELOPMENT
METABOLIC BECOMES POLYNOVO WITH $18m CASH
MEDIMMUNE EVALUATES NORWOOD VIROSOMAL VACCINE
NEUREN COMPLETES PHASE III GLYPROMATE DOSING
PROTEOME HALTS PROSTATE CANCER DIAGNOSTIC
GENETIC TECHNO ENFORCES CANCER TEST RIGHTS
GRAEME KAUFMAN: $400m FUND DELAYED, STILL BULLISH
TISSUE THERAPIES TO START PERTH TRIAL
GIACONDA HALTS PHASE IIa HEPATITIS C TRIAL
HUNTER IMMUNOLOGY READY FOR PHASE III COPD TRIAL
AVITA’S RECELL NEARS CHINESE REGISTRATION
PROGEN SPINS OUT PHARMASYNTH DRUG MANUFACTURING
SANOFI-AVENTIS PAYS $16m PLUS COSTS FOR UNILIFE’S SYRINGE
JUNE TOP 20 BEATS ALL ORDS; CHEMGENEX UP 30%, PORTLAND DOWN 57%
ANTISENSE, TEVA DATA: PHASE II MS DRUG SUCCESS
21 Posts
21 Posts
33 Posts
12 Posts
15 Posts
5 Posts
18 Posts
9 Posts
8 Posts
2 Posts
2 Posts
9 Posts
7 Posts
28 Posts
38 Posts
32 Posts
13 Posts
1 Posts
Email Subscription
Receive e-mail notifications of new posts on this blog:
[ View Blog Summary ] [ Create A New Post ]
Biotech Daily Editor's Blogs
I have no other blogs :(
Moderated by Biotech Daily Editor
